The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.
Min Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Rui Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Sameer Doshi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kelly S. Oliner
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Steven Kathman
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Per Olsson Gisleskog
Consultant or Advisory Role - Amgen
Sarita Dubey
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yizhou Jiang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ross C. Donehower
Research Funding - Amgen
Timothy Iveson
Research Funding - Amgen
Other Remuneration - Amgen
Elwyn Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen